SCHEMBL24133307

SCHEMBL24133307

Oc1c(F)cc(I)c(Cl)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.35
HPGD P15428 2/20 0.35
TSHR P16473 2/20 0.35
TTR P02766 1/20 0.35
CASP1 P29466 1/20 0.35
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
MAPK1 P28482 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31
CYP2C19 P33261 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HIF1A Q16665 1/20 0.31
IDO1 P14902 1/20 0.31
GRIN2D O15399 2/20 0.31
GRIN3B O60391 2/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2A Q12879 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8572714 0.80 TTR (0.38) TTRERN1
SCHEMBL18167031 0.77 GRIN2D (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL18167025 0.75 GRIN2D (0.32) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30008043 0.74 THRB (0.36) HSD17B10HPGDTSHRCASP1ESR1
SCHEMBL25027697 0.74 THRB (0.36) HSD17B10HPGDTSHRCASP1ESR1
SCHEMBL24133308 0.74 CYP3A4 (0.46) HSD17B10HPGDTSHRCASP1ESR1
SCHEMBL814774 0.71 IDO1 (0.42) HSD17B10HPGDTSHRTTRCASP1
SCHEMBL24133309 0.71 ERN1 (0.53) ERN1
SCHEMBL22138539 0.70 TTR (0.43) TTRACHEBACE1ERN1
SCHEMBL8571604 0.70 HSD17B10 (0.39) HSD17B10HPGDTSHRTTRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242473-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230242473-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230242473-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 US disclosed
WO-2021257834-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 WO disclosed
WO-2021257834-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242473-A1 THYROMIMETICS TPO, THOP1, THRB HSD17B10 1258/4885HPGD 224/4885TSHR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.